- Home
- ENSC vs CNSP Comparison
ENSC vs CNSP Comparison
Compare ENSC & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- CNSP
- Stock Information
- Founded
- ENSC 2003
- CNSP 2017
- Country
- ENSC United States
- CNSP United States
- Employees
- ENSC N/A
- CNSP N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- CNSP Health Care
- Exchange
- ENSC Nasdaq
- CNSP Nasdaq
- Market Cap
- ENSC 4.9M
- CNSP 5.6M
- IPO Year
- ENSC N/A
- CNSP 2019
- Fundamental
- Price
- ENSC $2.16
- CNSP $0.86
- Analyst Decision
- ENSC
- CNSP Hold
- Analyst Count
- ENSC 0
- CNSP 1
- Target Price
- ENSC N/A
- CNSP N/A
- AVG Volume (30 Days)
- ENSC 53.2K
- CNSP 178.2K
- Earning Date
- ENSC 08-13-2025
- CNSP 08-13-2025
- Dividend Yield
- ENSC N/A
- CNSP N/A
- EPS Growth
- ENSC N/A
- CNSP N/A
- EPS
- ENSC N/A
- CNSP N/A
- Revenue
- ENSC $6,224,081.00
- CNSP N/A
- Revenue This Year
- ENSC N/A
- CNSP N/A
- Revenue Next Year
- ENSC $1,381.48
- CNSP N/A
- P/E Ratio
- ENSC N/A
- CNSP N/A
- Revenue Growth
- ENSC 256.35
- CNSP N/A
- 52 Week Low
- ENSC $1.62
- CNSP $0.73
- 52 Week High
- ENSC $14.67
- CNSP $82.50
- Technical
- Relative Strength Index (RSI)
- ENSC 46.61
- CNSP 48.03
- Support Level
- ENSC $1.97
- CNSP $0.85
- Resistance Level
- ENSC $2.40
- CNSP $0.95
- Average True Range (ATR)
- ENSC 0.16
- CNSP 0.08
- MACD
- ENSC 0.00
- CNSP 0.02
- Stochastic Oscillator
- ENSC 44.19
- CNSP 59.17
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.